Compare · BMRA vs OCDX
BMRA vs OCDX
Side-by-side comparison of Biomerica Inc. (BMRA) and Ortho Clinical Diagnostics Holdings plc (OCDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BMRA and OCDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- OCDX is the larger of the two at $4.08B, about 473.6x BMRA ($8.6M).
- BMRA has hit the wire 7 times in the past 4 weeks while OCDX has been quiet.
- OCDX has more recent analyst coverage (8 ratings vs 1 for BMRA).
- Company
- Biomerica Inc.
- Ortho Clinical Diagnostics Holdings plc
- Price
- $1.82-2.15%
- $17.64+0.46%
- Market cap
- $8.6M
- $4.08B
- 1M return
- -22.22%
- -
- 1Y return
- -43.13%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 7
- 0
- Recent ratings
- 1
- 8
Biomerica Inc.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
Ortho Clinical Diagnostics Holdings plc
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.
Latest BMRA
- SEC Form DEF 14A filed by Biomerica Inc.
- Biomerica Reports First Quarter Fiscal 2027 Financial Results
- SEC Form 10-Q filed by Biomerica Inc.
- SEC Form 8-K filed by Biomerica Inc.
- SEC Form EFFECT filed by Biomerica Inc.
- SEC Form EFFECT filed by Biomerica Inc.
- Amendment: SEC Form 10-K/A filed by Biomerica Inc.
- SEC Form S-3 filed by Biomerica Inc.
- SEC Form S-3 filed by Biomerica Inc.
- SEC Form 3 filed by new insider Qu Xiaoxuan
Latest OCDX
- SEC Form 15-12B filed by Ortho Clinical Diagnostics Holdings plc
- SEC Form 4: Iskra Michael S. returned 150,000 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Busky Joseph M
- SEC Form 4: Schlesinger Michael A. returned 87,637 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Palaniappan Chockalingam
- SEC Form 4: Yates Robert Clifton returned 323,880 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Smith Christopher M returned 367,360 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Dilsaver Evelyn S returned 5,200 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Mac Mahon Thomas P returned 141,853 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Labrum Ronald K returned 109,985 units of Ordinary Shares to the company, closing all direct ownership in the company